Yoon In-Kyu, Alera Maria Theresa, Lago Catherine B, Tac-An Ilya A, Villa Daisy, Fernandez Stefan, Thaisomboonsuk Butsaya, Klungthong Chonticha, Levy Jens W, Velasco John Mark, Roque Vito G, Salje Henrik, Macareo Louis R, Hermann Laura L, Nisalak Ananda, Srikiatkhachorn Anon
Department of Virology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.
Philippines-AFRIMS Virology Research Unit, Cebu City, Philippines.
PLoS Negl Trop Dis. 2015 May 7;9(5):e0003764. doi: 10.1371/journal.pntd.0003764. eCollection 2015 May.
Chikungunya virus (CHIKV) is a globally re-emerging arbovirus for which previous studies have indicated the majority of infections result in symptomatic febrile illness. We sought to characterize the proportion of subclinical and symptomatic CHIKV infections in a prospective cohort study in a country with known CHIKV circulation.
METHODS/FINDINGS: A prospective longitudinal cohort of subjects ≥6 months old underwent community-based active surveillance for acute febrile illness in Cebu City, Philippines from 2012-13. Subjects with fever history were clinically evaluated at acute, 2, 5, and 8 day visits, and at a 3-week convalescent visit. Blood was collected at the acute and 3-week convalescent visits. Symptomatic CHIKV infections were identified by positive CHIKV PCR in acute blood samples and/or CHIKV IgM/IgG ELISA seroconversion in paired acute/convalescent samples. Enrollment and 12-month blood samples underwent plaque reduction neutralization test (PRNT) using CHIKV attenuated strain 181/clone25. Subclinical CHIKV infections were identified by ≥8-fold rise from a baseline enrollment PRNT titer <10 without symptomatic infection detected during the intervening surveillance period. Selected CHIKV PCR-positive samples underwent viral isolation and envelope protein-1 gene sequencing. Of 853 subjects who completed all study procedures at 12 months, 19 symptomatic infections (2.19 per 100 person-years) and 87 subclinical infections (10.03 per 100 person-years) occurred. The ratio of subclinical-to-symptomatic infections was 4.6:1 varying with age from 2:1 in 6 month-5 year olds to 12:1 in those >50 years old. Baseline CHIKV PRNT titer ≥10 was associated with 100% (95%CI: 46.1, 100.0) protection from symptomatic CHIKV infection. Phylogenetic analysis demonstrated Asian genotype closely related to strains from Asia and the Caribbean.
Subclinical infections accounted for a majority of total CHIKV infections. A positive baseline CHIKV PRNT titer was associated with protection from symptomatic CHIKV infection. These findings have implications for assessing disease burden, understanding virus transmission, and supporting vaccine development.
基孔肯雅病毒(CHIKV)是一种在全球范围内再度出现的虫媒病毒,此前的研究表明,大多数感染会导致有症状的发热疾病。我们试图在一个已知有CHIKV传播的国家进行的一项前瞻性队列研究中,确定亚临床和有症状的CHIKV感染的比例。
方法/研究结果:2012年至2013年,在菲律宾宿务市,对年龄≥6个月的受试者进行了一项前瞻性纵向队列研究,以对急性发热疾病进行社区主动监测。有发热病史的受试者在急性发病时、第2天、第5天和第8天就诊时以及在3周恢复期就诊时接受临床评估。在急性发病时和3周恢复期就诊时采集血液样本。有症状的CHIKV感染通过急性血液样本中CHIKV PCR检测呈阳性和/或配对的急性/恢复期样本中CHIKV IgM/IgG ELISA血清学转换来确定。入组时和12个月时的血液样本使用CHIKV减毒株181/clone25进行蚀斑减少中和试验(PRNT)。亚临床CHIKV感染通过在基线入组PRNT滴度<10的情况下,在中间监测期内未检测到有症状感染的情况下,从基线上升≥8倍来确定。对选定的CHIKV PCR阳性样本进行病毒分离和包膜蛋白-1基因测序。在12个月时完成所有研究程序的853名受试者中,发生了19例有症状感染(每100人年2.19例)和87例亚临床感染(每100人年10.03例)。亚临床感染与有症状感染的比例为4.6:1,随年龄而异,6个月至5岁的儿童为2:1,50岁以上的人群为12:1。基线CHIKV PRNT滴度≥10与预防有症状的CHIKV感染的保护率为100%(95%CI:46.1,100.0)相关。系统发育分析表明,亚洲基因型与来自亚洲和加勒比地区的毒株密切相关。
亚临床感染占CHIKV总感染的大多数。基线CHIKV PRNT滴度呈阳性与预防有症状的CHIKV感染相关。这些发现对评估疾病负担、了解病毒传播和支持疫苗开发具有重要意义。